NR 585NP Week 4 TASMINH4 Article Appraisal Example

Article Appraisal: The TASMINH4 Trial of Self-Monitoring and Telemonitoring for Medication Titration, and the One Sentence in Its Conclusion the Design Can and Cannot Carry

Student Name

College of Nursing, Chamberlain University

NR 585NP: Research Methods and Evidence-Based Practice for Advanced Nursing Practice

Instructor Name

Month Day, Year

Article Appraisal: The TASMINH4 Trial of Self-Monitoring and Telemonitoring for Medication Titration, and the One Sentence in Its Conclusion the Design Can and Cannot Carry

The Claim on the Table

McManus et al. (2018) conclude, in substance, that self-monitoring of blood pressure, with or without telemonitoring, when used by general practitioners to titrate antihypertensive medication in people with poorly controlled blood pressure, leads to lower blood pressure than titration guided by clinic readings. This appraisal asks whether that sentence was earned, and what a practice like Cedar Family Practice could and could not take from it.

The Design, Named

TASMINH4 was an unblinded, randomized controlled trial in 142 general practices in England, with 1,182 adults whose blood pressure was above 140/90 mm Hg while on treatment. Participants were randomly assigned to three groups: self-monitoring, with readings reviewed by the practice to guide medication; self-monitoring with telemonitoring, where readings were sent electronically; and usual care, with titration based on clinic readings. The primary outcome was clinic systolic pressure at 12 months.

What the Design Allows and What It Forbids

Randomization across a large number of participants makes it reasonable to attribute a difference in blood pressure between groups to the way titration was guided. That is what the design allows.

It forbids several things. First, it cannot say that self-monitoring prevents strokes or heart attacks, because it measured blood pressure, not events, and followed participants for one year. Second, it cannot say that cuffs alone lower blood pressure, because in both intervention arms the readings were used by clinicians to change medication. The claim is about self-monitoring as a basis for titration. Third, because participants and clinicians knew their group, it cannot rule out that clinicians in the intervention arms were simply more attentive. The outcome was measured with automated clinic readings, which reduces, but does not remove, that concern.

Sample and Setting: Who It Reaches

The trial enrolled people in English general practice whose doctors titrated medication, with a target based on 140/90. Cedar uses 130/80 and plans to have a nurse adjust medication. The participants had agreed to join a trial and were willing to self-monitor. Those differences do not make the result useless for Cedar, but they mean the effect at Cedar may be different. A practice whose patients are less willing to monitor, or who have less access to the portal, could see a smaller effect.

Numbers Turned Into Consequences

At 12 months, mean clinic systolic pressure was about 140 mm Hg in usual care, 137 mm Hg with self-monitoring and 136 mm Hg with telemonitoring. The adjusted differences against usual care were about 3.5 mm Hg for self-monitoring and 4.7 mm Hg for telemonitoring, with 95% confidence intervals that did not cross zero.

What would that mean for Cedar's 268 patients with uncontrolled readings? A 3 to 5 mm Hg fall in average systolic pressure is modest for one patient and meaningful across a panel. A large meta-analysis of blood pressure lowering trials found that each 10 mm Hg reduction in systolic pressure was associated with about a fifth fewer major cardiovascular events (Ettehad et al., 2016). By that estimate, a reduction of 3.5 mm Hg would be expected to lower events by somewhat less than a tenth, if the reduction were sustained and the relationship held at this level. That is an inference from a different body of evidence, not something TASMINH4 measured, and it is stated here as an estimate of what the change might be worth.

The lower end of each confidence interval was close to 1 or 2 mm Hg. The true effect could therefore be small. The upper end was around 6 or 7 mm Hg. A practice planning on the basis of this trial should expect a benefit in the low single digits.

Statistical Against Clinical Importance

The differences were statistically significant. Whether a difference of 3.5 mm Hg justifies a new service depends on cost and effort, which the trial did not decide for Cedar. The appraisal should not read the p value as a measure of importance in either direction.

Proxies and Subgroups

Clinic systolic pressure is a proxy for cardiovascular events. It is a well-established one, which is why blood pressure trials use it, but the appraisal keeps it labeled as a proxy. The paper reports some secondary outcomes and analyses; none of them change the primary result, and the appraisal does not rely on any subgroup finding, because the trial was not built to test differences between subgroups.

Strengths and Threats to Validity

Strengths: randomization, a large sample, many practices, an automated outcome measure and a 12-month follow-up.

Threats: no blinding of participants or clinicians; a population of trial volunteers; and a care system with different targets and different staff roles from Cedar's. Loss to follow-up was modest and similar across groups, which limits bias from dropout.

How This Paper Fits the Wider Set

TASMINH4 is consistent with the individual patient data meta-analysis by Tucker et al. (2017), which found that self-monitoring lowered blood pressure more when it was combined with clinician action than when used alone. It is one of the larger trials in the set and one of the few with three arms, which lets it compare telemonitoring directly.

What Cedar Would Need to Check Before Using It

Three questions follow from the appraisal. First, would a nurse adjusting medication under protocol make the same changes a general practitioner made in the trial? The trial's titration schedule is published and could be compared with Cedar's draft protocol. Second, would Cedar's patients send readings as reliably as volunteers did? A small pilot would answer that, and the count of patients still sending readings at three months would be the first sign. Third, would a 130/80 target change the effect? Lowering the target means more medication steps, which could increase the effect or the side effects. None of these is a flaw in the trial. They are the distance between its setting and Cedar's.

The Verdict

The sentence was earned within limits. TASMINH4 supports the claim that self-monitoring used to guide medication changes lowers clinic systolic pressure by a few mm Hg over a year compared with titration on clinic readings, in English primary care with a 140/90 target. It does not support saying that cuffs alone lower pressure, that self-monitoring prevents strokes, or that a nurse-led version at 130/80 would produce the same effect. For Cedar, the paper is strong support for testing a version in which someone acts on home readings, and weak support for any claim beyond that.

References

Ettehad, D., Emdin, C. A., Kiran, A., Anderson, S. G., Callender, T., Emberson, J., Chalmers, J., Rodgers, A., & Rahimi, K. (2016). Blood pressure lowering for prevention of cardiovascular disease and death: A systematic review and meta-analysis. The Lancet, 387(10022), 957-967. https://doi.org/10.1016/S0140-6736(15)01225-8

McManus, R. J., Mant, J., Franssen, M., Nickless, A., Schwartz, C., Hodgkinson, J., Bradburn, P., Farmer, A., Grant, S., Greenfield, S. M., Heneghan, C., Jowett, S., Martin, U., Milner, S., Monahan, M., Mort, S., Ogburn, E., Perera-Salazar, R., Shah, S. A., ... Hobbs, F. D. R. (2018). Efficacy of self-monitored blood pressure, with or without telemonitoring, for titration of antihypertensive medication (TASMINH4): An unmasked randomised controlled trial. The Lancet, 391(10124), 949-959. https://doi.org/10.1016/S0140-6736(18)30309-X

Tucker, K. L., Sheppard, J. P., Stevens, R., Bosworth, H. B., Bove, A., Bray, E. P., Earle, K., George, J., Godwin, M., Green, B. B., Hebert, P., Hobbs, F. D. R., Kantola, I., Kerry, S. M., Leiva, A., Magid, D. J., Mant, J., Margolis, K. L., McKinstry, B., ... McManus, R. J. (2017). Self-monitoring of blood pressure in hypertension: A systematic review and individual patient data meta-analysis. PLOS Medicine, 14(9), e1002389. https://doi.org/10.1371/journal.pmed.1002389